BTRC and infection: mTOR inhibitor, PP242, treatment directly inhibits CK1α kinase activity and disrupts the LT interaction with both β-TrCP and Skp2, which explains a greater inhibition effect on LT destruction complex, resulting in enhanced MCPyV replication and infection shown in the previous studies (7, 8).